Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years

Sponsor

University of Zurich (Other)

Overall Status

Completed

CT.gov ID

NCT03561675

Collaborator

National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov (Other)

349

Enrollment

Location

Arms

15.5

Actual Duration (Months)

22.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Randomized, placebo controlled trial evaluating efficacy of acetazolamide in preventing acute mountain sickness in lowlanders older than 40 years travelling from 760 m to 3'100 m.

Condition or Disease	Intervention/Treatment	Phase
Acute Mountain Sickness	Drug: ACETAZOLAMIDE oral capsule Drug: Placebo oral capsule	Phase 4

Detailed Description

This is a randomized, placebo-controlled, double-blind parallel trial evaluating the efficacy of acetazolamide prophylaxis in reducing the incidence of acute mountain sickness (AMS) in lowlanders older than 40 years travelling to altitude. Participants living in the Bishkek area, Kyrgyzstan (760m), will be transferred by car within 4h to the Tuja Ashu high altitude clinic (3'100 m), and stay there for 2 days. Acetazolamide 375mg/day (or placebo), will be administered before departure at 760 m and during the stay at altitude. Outcomes will be assessed during the stay at 3'100 m.

An interim analysis will be carried out when 80 participants will have completed the study or after the first year. The Peto's method will be used and the trial will be stopped when pre-specified futility boundaries were crossed.

Study Design

Study Type:

Interventional

Actual Enrollment :

349 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Prevention

Official Title:

Acetazolamide for Prevention of Acute Mountain Sickness in Healthy Lowlanders Older Than 40 Years. Randomized Trial.

Actual Study Start Date :

May 15, 2018

Actual Primary Completion Date :

Aug 31, 2019

Actual Study Completion Date :

Aug 31, 2019

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: ACETAZOLAMIDE oral capsule Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m	Drug: ACETAZOLAMIDE oral capsule Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
Placebo Comparator: PLACEBO oral capsule Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m.	Drug: Placebo oral capsule Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m

Arm

Intervention/Treatment

Active Comparator: ACETAZOLAMIDE oral capsule

Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m

Drug: ACETAZOLAMIDE oral capsule

Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m

Placebo Comparator: PLACEBO oral capsule

Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m.

Drug: Placebo oral capsule

Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m

Outcome Measures

Primary Outcome Measures

Acute mountain sickness (AMS), incidence [Day 1 to 3 at 3'100m]
Difference between acetazolamide and placebo group in the incidence of AMS during the stay at 3'100 m.

Secondary Outcome Measures

Acute mountain sickness (AMS), severity assessed by the Lake Louise score [Day 1 to 3 at 3'100m]
Difference between acetazolamide and placebo group in the severity of AMS during the stay at 3'100 m. The severity of acute mountain sickness (AMS) will be assessed by the Lake Louise questionnaire (LLS), a validated questionnaire about AMS. The severity will be calculated when the presence of headache and at least one of the following symptoms is present: gastrointestinal upset, fatigue or weakness, dizziness or lightheadedness and difficulty sleeping. Each of the five questions is asked with the corresponding 0 to 3 rating of the response (0 = Not present, 1 = mild, 2 = moderate, 3 = severe). The sum of the responses on these questions is then calculated, resulting in the AMS severity.
Acute mountain sickness (AMS) at 760 m with and without acetazolamide, severity [Day 3 at 760 m]
Difference between acetazolamide and placebo group in the severity of AMS at 760 m.
Altitude related adverse health effects (ARAHE), incidence [Day 1 to 3 at 3'100m]
Difference between acetazolamide and placebo group in the incidence of ARAHE during the stay at 3'100 m. ARAHE are defined as the following: Moderate to severe AMS (Lake Louise score ≥3 and/or Environmental Symptoms questionnaire AMSc score ≥0.7) and/or any of the following: Severe hypoxemia (SpO2 at rest <80% for >30 min or <75% for >15 min, exercise oxygen desaturation SpO2 <75% for >1 min accompanied by symptoms or signs of hypoxemia) Symptomatic cardiovascular disease (arterial blood pressure systolic >200 mmHg, diastolic >110 mmHg not responding to blood pressure lowering drugs within 1 hr; chest pain with ECG signs of ischemia or new onset arrhythmia) Withdrawal from the study by the decision of the independent physician for safety reasons or by the patient.
Spirometric measurement of forced expiratory volume in one second [Day 2 at 760m and day 2 at 3'100m]
Difference in altitude-induced change in the forced expiratory volume in one second between the acetazolamide and placebo group
Arterial partical pressure of oxygen [Day 2 at 760m and day 2 at 3'100m]
Difference in altitude-induced changes in arterial partical pressure of oxygen between the acetazolamide and placebo group
Drug side effects [Day 1 to 3 at 3'100m]
Difference between acetazolamide and placebo group in the incidence of medication side effects during the stay at 3'100 m.

Eligibility Criteria

Criteria

Ages Eligible for Study:

40 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Healthy men and women, age 40-75 yrs, without any disease and need of medication.
Born, raised and currently living at low altitude (<800m).
Written informed consent.
Kyrgyz ethnicity

Exclusion Criteria:

Any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure.
Any condition that may interfere with protocol compliance including current heavy smoking (>20 cigarettes per day or >20 pack-years with active smoking during the last 10 years), regular use of alcohol.
Allergy to acetazolamide and other sulfonamides.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	National Center of Cardiology and Internal Medicine	Bishkek		Kyrgyzstan	720040

Sponsors and Collaborators

University of Zurich
National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov

Investigators

Study Chair: Konrad E Bloch, MD, University Hospital, Zürich
Study Director: Talant M Sooronbaev, MD, National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan
Principal Investigator: Michael Furian, MSc, University Hospital, Zürich